A comparative study of efficacy and safety of intravenous ferric carboxymaltose versus iron sucrose in the treatment of iron deficiency anaemia of pregnancy in a tertiary care hospital
Keywords:Anaemia, Ferric carboxymaltose, Haemoglobin, Iron sucrose, Serum ferritin
Background: Anaemia is a global public health problem. To optimize iron delivery in pregnancy, new intravenous complexes like Ferric carboxymaltose (FCM) have been developed in the few years. This study aims to compare the efficacy and safety of FCM vs the iron sucrose during pregnancy.
Methods: This study was conducted in the Department of Obstetrics and Gynaecology, Shri Maharaja Gulab Singh (S.M.G.S.) Hospital, Government Medical College Jammu, Jammu and Kashmir over a period of 1 year. 100 pregnant females with haemoglobin (Hb) in the range 7-9.9 g/dl between 28 to 36-week gestation, were selected randomly out of which 50 were administered FCM (Group A) and 50 were administered Iron Sucrose (Group B). Hb and serum ferritin were assessed 2 weeks and 4 weeks after treatment and side effects of each drug was studied.
Results: The rise in mean Hb level at 2 weeks and 4 weeks in FCM group was significantly higher as compared to Iron Sucrose group (1.09 versus 0.52 g/dl and 1.80 versus 1.09 g/dl, respectively). Similarly, the rise in mean serum ferritin level at 2 weeks and 4 weeks was more in FCM as compared to Iron Sucrose group (144.25 vs 95.84 mcg/L and 121.31 vs 84.46 mcg/L, respectively). The adverse reactions were observed in 30% of patients in FCM group and 48% patients in iron sucrose group.
Conclusions: Ferric carboxymaltose was found to be more safe and efficacious as compared to iron sucrose.
Baby A, Venugopal J, D'silva R, Chacko S, Vineesha PV, Kumary TV. Knowledge on management of anaemia during pregnancy: a descriptive study. Arch Med Health Sci. 2014; 2:140-4.
World Health Organisation. Micronutrient deficiencies: prevention and control guidelines. Geneva: World Health Organization. 2015.
FOGSI General Clinical Practice Recommendations. Management of iron deficiency anaemia in pregnancy. 2016.
Froessler B, Collingwood J, Hodyl NA, Dekker G. Intravenous ferric carboxymaltose for anaemia in pregnancy. BMC Pregnancy Childbirth. 2014;14(1):115.
Dev SM, Sharma AN. Food security in India: performance, challenges and policies. Oxfam India Working Papers Series. 2010;4(1):1-42.
Friedrisch JR, Cancado RD. Intravenous ferric carboxymaltose for the treatment of iron deficiency anaemia. Rev Bras Hematol Hemoter. 2015;37(6):400-5.
Gautham KSK. Intravenous Iron Sucrose. World J Anaemia. 2017; 1(1):20-2.
Rudra S, Chandna A, Nath J. Comparison of intravenous iron sucrose with oral iron in pregnant women with iron deficiency anaemia. Int J Reprod Contracept Obstet Gynecol. 2016;5(3):747-51.
Toblli JE, Angerosa M. Optimizing iron delivery in the management of anaemia: patient considerations and the role of ferric carboxymaltose. Drug Design Development Therapy. 2014;8:2475-91.
Garg R, Nigam A, Agrawal P, Nigam A, Agrawal R. Iron carboxymaltose: a safe and effective molecule to combat anaemia in pregnancy. Int J Curr Res Aca Rev. 2016;4(2):124-30.
Reveiz L, Gyte GM, Cuervo LG, Casasbuenas A. Treatments for iron-deficiency anaemia in pregnancy. Cochrane Database Syst Rev. 2011;(10):CD003094.
Singh U, Singh SP, Niranjan A, Sharma S, Srivastava A, Kumar H. Prevalence of anaemia in pregnancy in Rural Western U.P: a prospective study. IJPHD. 2011;2(2):60-3.
Christoph P, Schuller C, Studer H, Irion O, De Tejada BM, Surbek D. Intravenous iron treatment in pregnancy: comparison of high-dose ferric carboxymaltose vs. iron sucrose. J Perinat Med. 2012;40(5):469-74.
Patel J, Patel K, Sharma A, Date SK. Comparison of intravenous iron sucrose and ferric carboxymaltose therapy in iron deficiency anaemia during pregnancy and post-partum period. JPSBR. 2015;5(3):239-43.
Garg R, Nigam A, Agrawal P, Nigam A, Agrawal R. Iron Carboxymaltose: a safe and effective molecule to combat anaemia in pregnancy. Int J Curr Res Aca Rev. 2016;4(2):124-30.
Metgud MC, Metgud SB, Bellad MB, Metgud SH. Comparison of efficacy and safety of intravenous ferric carboxymaltose vs iron sucrose in the treatment of antepartum iron deficiency anaemia: a randomized controlled trial. J South Asian Feder Obst Gynae. 2016;8(4):314-8.
Boughton S, Chen L, Kidson-Gerber G, Curtain C, Zaidi STR, Henry A. Intravenous iron sucrose and ferric carboxymaltose in pregnant patients: an observational study of maternal efficacy and tolerance. J Pharm Pract Res. 2017;47(6):419-25.
Joshi SD, Chandana N. Intravenous iron therapy in pregnancy: a comparison between intravenous ferric carboxymaltose and iron sucrose. EJBPS. 2017;4(01):323-8.
Maheshwari B, Mahtab V, Tyagi S, Tyagi P. Evaluation of efficacy, safety and cost effectiveness of oral iron and injectable iron sucrose and ferric carboxy maltose in pregnant women in 2nd and 3rd trimester in anaemia. Indian J Obstet Gynecol Res. 2017;4(1):96-100.
US Food and Drug Administration. Injectafer (Ferric Carboxymaltose) approval letter. Available at http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203565Origls000Approv.pdf. Accessed 9th January 2013.
Lyseng-Williamson KA, Keating GM. Ferric carboxymaltose: a review of its use in iron-deficiency anaemia. Drugs. 2009;69(6):739-56.